Most Popular

Most Popular News

February 12, 2018

 Several experts discussed imaging, biopsy, the use of active surveillance, and the preservation of renal function and other aspects of oncologic and functional follow-up.

Read more

February 9, 2018

A better understanding of the genomics of this malignancy, as well as improved imaging techniques and developments of new therapeutics, is pushing the evolution of the diagnosis and treatment of advanced prostate cancer.

Read more

February 9, 2018

Two placebo-controlled trials found that treatment of nonmetastatic castration-resistant prostate cancer with androgen signaling inhibitors (ASIs) delays the development of metastatic disease and may prolong survival.

Read more
February 1, 2018

Dr. Christian Kollmannsberger, a medical oncologist with the British Columbia Cancer Centre and clinical professor at the University of British Columbia, will discuss management of stage II testicular cancer during his keynote lecture,

Read more

February 1, 2018

Dr. Robert J. Motzer will discuss the development and approval of tyrosine-kinase inhibitors (TKIs) for renal cell carcinoma (RCC) during his keynote lecture on February 10, touching on pivotal trials and controversies.

Read more

February 1, 2018

Dr. Seth P. Lerner, the Beth and Dave Swalm Chair in Urologic Oncology at Baylor College of Medicine, will discuss the impact of The Cancer Genome Atlas on bladder cancer research and the oncology field as a whole during his keynote lecture on February 9.

Read more
February 1, 2018

The ASCO MOC app allows easy access to self-assessment questions designed for your mobile device, as well as courses that offer an engaging technique to help oncologists retain information with a pulsed-education approach. 

Read more
February 1, 2018

CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has signed formal collaboration agreements with seven other nonprofit associations and two federal agencies.

Read more
February 1, 2018

ASCO has issued the “ASCO Position Statement on Addressing the Affordability of Cancer Drugs” to contribute to the national dialogue on rising cancer drug prices, asserting that any solutions must also preserve patients’ access to care and foster innovation.

Read more
February 1, 2018

ASCO's TAPUR Study continues to expand and now has more than 450 participants enrolled on study drug, new partnerships, and a revised protocol to lower the age of eligibility, and will soon have more than 100 sites.

Read more
February 1, 2018

The U.S. Food and Drug Administration and ASCO leveraged their combined knowledge for the third FDA-ASCO Semi-Annual Hematology and Oncology Fellows Day Workshop.

Read more
February 1, 2018

The phase III PROSELICA study, which assessed the noninferiority of cabazitaxel 20 mg/m2 versus C25 in post-docetaxel patients with mCRPC, confirmed the activity of cabazitaxel and demonstrated that a dose reduction retains significant clinical benefits for these patients.

Read more
February 7, 2017

The ASCO Daily News podcast is dedicated to providing ASCO members and meeting attendees more of the high-quality information they’ve come to expect from the Daily News.

Read more
February 1, 2018

The Genitourinary Cancers Symposium Clinical Corner allows expert physicians to answer questions posed by an attendee during previous Best of ASCO Meetings. 

Read more
February 1, 2018

Patient engagement in decision-making, and satisfaction rates overall, are higher when treatment is administered by a multidisciplinary team.

Read more
February 1, 2018

Dr. William W. Mayo-Smith, vice chair of radiology at Brigham & Women’s Hospital and professor of radiology at Harvard Medical School, will review methods for detecting and diagnosing adrenocortical carcinomas in his keynote presentation.

Read more
February 1, 2018

Dr. Matthew D. Ingham shares his reasons for attending the GU Cancers Symposium and his advice for newer attendees.

Read more
February 1, 2018

Merit Awards are awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to an ASCO-sponsored or cosponsored meeting and recognized for its scientific merit. 

Read more
February 1, 2018

Dr. Rana R. McKay discusses why she continues to attend the GU Cancers Symposium and shares her advice for newer attendees.

Read more
February 1, 2018

Based on the FIRSTANA and PROSELICA studies, cabazitaxel is a potent chemotherapeutic agent in the first- and second-line treatment of patients with mCRPC. 

Read more